CLINICAL TRIAL: TREATMENT OF MELANOMA WITH WILD-TYPE P53 AND A 100B USING PENTA

临床试验：使用 PENTA 使用野生型 P53 和 A 100B 治疗黑色素瘤

• 批准号: 7951182
• 负责人: EDWARD A. SAUSVILLE
• 金额: $ 0.96万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-03-01 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7951182
• 关键词: Clinical Research; Clinical Treatment; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Disease Progression; Funding; Grant; Institution; Mutation; Pentamidine; Pentas; Pharmaceutical Preparations; Protozoa; Refractory; Relapse; Research; Research Personnel; Resources; Source; TP53 gene; Time; Toxic effect; United States National Institutes of Health; melanoma; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Pentamidine is a clinically available anti-protozoal agent, which also inhibits the interaction of wild type p53 and S100B; these are frequently expressed in melanomas. The primary objective is to determine the response rate of relapsed and/or refractory melanoma that has previously been defined to express detectable S100B and to have a wild-type p53 mutation. Secondary objectives include assessment of toxicities, observation of time to disease progression, and observation of effect of drug treatment on expression of S100B and p53.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 喷他脒是临床上可用的抗原生动物剂，其还抑制野生型p53和S100 B的相互作用;这些在黑色素瘤中频繁表达。主要目的是确定复发性和/或难治性黑色素瘤的缓解率，这些黑色素瘤先前已被定义为表达可检测的S100 B并具有野生型p53突变。次要目的包括评估毒性、观察疾病进展时间以及观察药物治疗对S100 B和p53表达的影响。